Astrazeneca PLC’s (AZN) Hold Rating Reiterated at Shore Capital

Shore Capital reiterated their hold rating on shares of Astrazeneca PLC (NYSE:AZN) in a report issued on Thursday morning.

Several other analysts have also weighed in on the stock. Cantor Fitzgerald reiterated a buy rating on shares of Astrazeneca PLC in a research note on Friday, October 28th. Bank of America Corp. reiterated a buy rating and set a $36.65 target price on shares of Astrazeneca PLC in a research note on Monday, July 18th. Citigroup Inc. reiterated a buy rating on shares of Astrazeneca PLC in a research note on Friday, September 23rd. Berenberg Bank reiterated a buy rating on shares of Astrazeneca PLC in a research note on Sunday, September 11th. Finally, Beaufort Securities reiterated a hold rating on shares of Astrazeneca PLC in a research note on Friday, August 26th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $37.61.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

Shares of Astrazeneca PLC (NYSE:AZN) traded down 0.235% during trading on Thursday, hitting $27.585. 1,561,834 shares of the stock were exchanged. The stock has a 50-day moving average of $30.57 and a 200 day moving average of $30.84. Astrazeneca PLC has a 12-month low of $26.97 and a 12-month high of $35.04. The stock has a market cap of $69.79 billion, a P/E ratio of 28.307 and a beta of 0.83.

Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, November 10th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.58. The business earned $5.70 billion during the quarter, compared to analyst estimates of $5.95 billion. Astrazeneca PLC had a net margin of 10.35% and a return on equity of 31.30%. The business’s revenue was down 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.03 earnings per share. Equities analysts predict that Astrazeneca PLC will post $3.02 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of AZN. Creative Planning increased its position in Astrazeneca PLC by 114.5% in the second quarter. Creative Planning now owns 28,228 shares of the company’s stock worth $852,000 after buying an additional 15,069 shares in the last quarter. NEXT Financial Group Inc increased its position in Astrazeneca PLC by 8.8% in the second quarter. NEXT Financial Group Inc now owns 6,305 shares of the company’s stock worth $190,000 after buying an additional 509 shares in the last quarter. New England Research & Management Inc. purchased a new position in Astrazeneca PLC during the second quarter worth approximately $777,000. Integrated Investment Consultants LLC increased its position in Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock worth $144,000 after buying an additional 275 shares in the last quarter. Finally, First Financial Bank N.A. Trust Division increased its position in Astrazeneca PLC by 7.3% in the second quarter. First Financial Bank N.A. Trust Division now owns 7,787 shares of the company’s stock worth $235,000 after buying an additional 530 shares in the last quarter. Institutional investors own 11.58% of the company’s stock.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

5 Day Chart for NYSE:AZN

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2016 Mideast Time.